Effects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal Women

20061,039 citationsJournal Articlebronze Open Access

Authors

Elizabeth Barrett‐Connor · University of California, San Diego

Lori Mosca · University of California, San Francisco

Peter Collins · University of California, San Francisco

Mary Jane Geiger · University of California, San Francisco

Deborah Grady · San Francisco VA Medical Center

Marcel Kornitzer

Michelle McNabb · University of California, San Francisco

Abstract

Raloxifene did not significantly affect the risk of CHD. The benefits of raloxifene in reducing the risks of invasive breast cancer and vertebral fracture should be weighed against the increased risks of venous thromboembolism and fatal stroke. (ClinicalTrials.gov number, NCT00190593 [ClinicalTrials.gov].).

Topics & Keywords

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 355, Issue 2, pp. 125-137

DOI: 10.1056/nejmoa062462

Field-Weighted Citation Impact: 63.75